13 unknown, 11 completed, 3 terminated, 2 not yet recruiting. 12 Phase 2, 7 Phase 3, 4 Phase 1, 4 Phase 4, 2 Not applicable.
Follow Acute Promyelocytic Leukemia: new trials by email Literature Review of Acute Promyelocytic Leukemia trials Research Report on Acute Promyelocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice Bone marrow or peripheral blood withdrawal for test comparison - Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult | Not applicable | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 75 | 2027-01-01 | 2026-10-09 |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-30 |
| A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA) - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Not yet recruiting | SDK Therapeutics, Inc. | 120 | 2026-01-01 | 2025-12-29 |
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients venetoclax - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 98 | 2023-08-01 | 2024-08-09 |
| Optimum Induction Therapy of Low-risk APL Etoposide, Daunorubicin - Acute Promyelocytic Leukemia, Induction Therapy | Not applicable | Unknown | Peking University People's Hospital | 74 | 2023-01-01 | 2024-05-10 |
| A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia SY-2101, Arsenic Trioxide - Acute Promyelocytic Leukemia | Phase 1 | Suspended | Syros Pharmaceuticals | 16 | 2021-09-17 | 2024-01-23 |
| Frontline Oral Arsenic Trioxide for APL Oral Arsenic Trioxide Formulation - Acute Promyelocytic Leukemia | Phase 2 | Unknown | The University of Hong Kong | 100 | 2021-01-01 | 2025-06-12 |
| Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia Arsenic Trioxide - Acute Promyelocytic Leukemia | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 100 | 2020-04-14 | 2022-01-04 | |
| The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project Acute Promyelocytic Leukemia | Unknown | The University of Hong Kong | 1000 | 2020-02-02 | 2022-10-04 | |
| Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Mylotarg, Arsenic Trioxide, All-trans retinoic acid - Acute Promyelocytic Leukemia | Phase 2 | Recruiting | Associazione Italiana Ematologia Oncologia Pediatrica | 89 | 2019-10-09 | 2024-04-15 |
| Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia Oral arsenic Trioxide, ATRA and ascorbic acid - Acute Promyelocytic Leukemia | Phase 2 | Unknown | The University of Hong Kong | 60 | 2018-08-15 | 2022-10-04 |
| Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy QoL questionnaires - Acute Promyelocytic Leukemia | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 161 | 2017-03-27 | 2021-02-08 | |
| Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Realgar-Indigo naturalis formula, all-trans retinoic acid, Arsenic trioxide - Acute Promyelocytic Leukemia | Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 110 | 2016-09-01 | 2021-09-08 |
| Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Arsenic trioxide, Idarubicin, Cytarabine - Acute Promyelocytic Leukemia | Phase 3 | Completed | Technische Universität Dresden | 133 | 2016-06-01 | 2026-05-29 |
| French Registry of First-line Treatment of Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia | Completed | Groupe Francophone des Myelodysplasies | 400 | 2015-10-01 | 2026-09-11 | |
| Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia | Unknown | First Affiliated Hospital of Harbin Medical University | 20 | 2014-10-01 | 2018-04-24 | |
| A Safety Study of SGN-CD33A in AML Patients HMA, SGN-CD33A - Acute Myelogenous Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | Seagen Inc. | 195 | 2013-07-01 | 2018-01-05 |
| Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia Health Related Quality of Life (HRQOL) measures - Acute Promyelocytic Leukemia | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2013-02-01 | 2014-10-02 | ||
| Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL ATRA+Arsenic, ATRA+Chemo - Acute Promyelocytic Leukemia | Phase 4 | Unknown | Shanghai Jiao Tong University School of Medicine | 738 | 2012-06-01 | 2019-08-19 |
| Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy Acute Promyelocytic Leukemia, Pregnancy | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 69 | 2012-03-07 | 2022-10-12 |
Showing 20 of 35. Sign in to see all of them.
Leukemia, Promyelocytic, Acute (35) · Leukemia (4) · Leukemia, Myeloid, Acute (3) · Recurrence (3) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hemostatic Disorders (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Myelomonocytic, Juvenile (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Primary Myelofibrosis (1)
Hemic and Lymphatic Diseases (35) · Leukemia, Myeloid (35) · Neoplasms by Histologic Type (35) · Hematologic Diseases (34) · Neoplasms (33) · Leukemia, Myeloid, Acute (32) · Leukemia (31) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2)
Arsenic Trioxide (14) · Tretinoin (12) · Idarubicin (4) · Cytarabine (2) · Gemtuzumab (2) · Mitoxantrone (2) · tamibarotene (2) · Ascorbic Acid (1) · Clofarabine (1) · Cyclophosphamide (1) · Daunorubicin (1) · Etoposide (1) · Hydroxyurea (1) · Mercaptopurine (1) · Methotrexate (1)
Gruppo Italiano Malattie EMatologiche dell'Adulto (6) · PETHEMA Foundation (3) · The University of Hong Kong (3) · Associazione Italiana Ematologia Oncologia Pediatrica (2) · Shanghai Jiao Tong University School of Medicine (2) · Alliance for Clinical Trials in Oncology (1) · Christian Medical College, Vellore, India (1) · CytRx (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · First Affiliated Hospital of Harbin Medical University (1) · Groupe Francophone des Myelodysplasies (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1) · NuRx Pharmaceuticals, Inc. (1)
United States (11) · Italy (9) · China (6) · Spain (6) · France (4) · Hong Kong (3) · Canada (2) · Germany (2) · Netherlands (2) · Belgium (1) · Czechia (1) · Denmark (1) · India (1) · Ireland (1) · Israel (1)
Sanz Miguel Angel, Dr (2) · Annamaria Testi, Dr (1) · Dan Douer, MD (1) · Esteve Jordi, Dr (1) · Fabio Efficace (1) · Fabio Efficace, PhD (1) · Fanco Locatelli, Prof (1) · Farhad Ravandi-Kashani, MD (1) · Harinder Gill, MD (1) · Harinder Singh Harry Gill, MBBS (1) · Harry Gill, MD (1) · Huaiyu Wang, Dr. (1) · JIong HU, M.D. (1) · Jae Park, MD (1)
PMID 20644121, PMID 23841729, PMID 27400939, PMID 10552940, PMID 11559723, PMID 12393590, PMID 19225113, PMID 19414681, PMID 19741727, PMID 19797519, PMID 20393132, PMID 20705755, PMID 21148082, PMID 21898784, PMID 21998212, PMID 22715121, PMID 24127444, PMID 25470713, PMID 25975975, PMID 28003274, PMID 28584252, PMID 29196412, PMID 29579321, PMID 31090936, PMID 31898521, PMID 33495363, PMID 34529768, PMID 36765318, PMID 39438322, PMID 39506905, PMID 39693517, PMID 40020161, PMID 40825164
2025 (2), 2017 (1), U10CA076001 (1)